Company / Cash & Equivalents
Genprex, Inc. Cash & Equivalents History
FY2017-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.6M
FY2024
5-year range
$1.6M / $6.7M
FY2020-FY2024
Trend
-76.2%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$2M in FY2024.
Remained stable around $2M over the past 7 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, cash & equivalents decreased 76.2% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -24.42 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $1.6M | -76.2% |
| FY2023 | $6.7M | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2018 | - | - |
| FY2017 | $1.6M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026